Testicular development of Zebu bulls after chronic treatment with a gonadotropin-releasing hormone agonist

被引:0
|
作者
Jiménez-Severiano, H
Mussard, ML
Fitzpatrick, LA
D'Occhio, MJ
Ford, JJ
Lunstra, DD
Kinder, JE [1 ]
机构
[1] Ohio State Univ, Dept Anim Sci, Columbus, OH 43210 USA
[2] James Cook Univ, Sch Biomed Sci, Townsville, Qld 4811, Australia
[3] Univ Queensland, Sch Anim Studies, Gatton, Qld 4343, Australia
[4] USDA ARS, Roman L Hruska US Meat Anim Res Ctr, Clay Ctr, NE 68933 USA
关键词
GATA-binding protein 4; gonadotropin-releasing hormone; male sexual function; sertoli cells; testis development; Zebu cattle;
D O I
暂无
中图分类号
S8 [畜牧、 动物医学、狩猎、蚕、蜂];
学科分类号
0905 ;
摘要
The objective was to compare testis characteristics of Zebu bulls treated with the GnRH agonist, deslorelin, at different times and for different durations during their development. An additional objective was to determine the usefulness of a stain for the transcription factor GATA-binding protein 4 (GATA-4) as a specific marker for Sertoli cell nuclei in cattle. Bulls (54) were allocated to nine groups (n = 6) and received s.c. deslorelin implants as follows: G1 = from birth to 3 mo of age; G2 = from 3 to 6 mo; G3 = from 6 to 9 mo; G4 = from 9 to 12 mo; G5 = from birth to 15 mo; G6 = from 3 to 15 mo; G7 = from 6 to 15 mo; G8 = from 12 to 15 mo; and G9 (control) = no implant. Bulls were castrated at 19 mo of age. Paraffin sections (10 mu m) were subjected to quantitative morphometry and GATA-4 immunohistochemistry. At castration, all bulls in the control group (6/6) had attained puberty (scrotal circumference ! 28 cm), whereas a smaller proportion (P < 0.05) had reached puberty in G2 (2/5) and G6 (1/ 6). Bulls in G2 and G6 also had a lesser (P < 0.05) testis weight compared with the control group. Total volume of seminiferous epithelium and total daily sperm production in G2 and G6 were only half that observed in the control group. Spermatids were observed in less than 50% of seminiferous tubules in G2, G6, and G7 compared with 82% in the control group (P < 0.05). Staining for GATA-4 was specific for and abundant in the Sertoli cell nucleus in both pre- and postpubertal bulls, and no other cell nucleus inside the seminiferous tubule was positive for GATA-4. Total number of Sertoli cells was not affected by treatment (P = 0.45), but nuclear volume was smaller in G2 and G6 (P < 0.05) compared with the control group. In conclusion, treatment of Zebu bulls with deslorelin had no apparent beneficial effect on testis development and delayed puberty when treatment was initiated at 3 mo of age. Staining for GATA-4 was a useful method for identifying and quantifying Sertoli cell nuclei in both pre- and postpubertal bulls.
引用
收藏
页码:2111 / 2122
页数:12
相关论文
共 50 条
  • [21] Hormonal and clinical effects of chronic gonadotropin-releasing hormone agonist treatment in polycystic ovary syndrome
    Szilágyi, A
    Homoki, J
    Bellyei, S
    Szabó, I
    [J]. GYNECOLOGICAL ENDOCRINOLOGY, 2000, 14 (05) : 337 - 341
  • [22] Medical treatment of uterocutaneous fistula with gonadotropin-releasing hormone agonist administration
    Seyhan, Ayse
    Ata, Baris
    Sidal, Bilhan
    Urman, Bulent
    [J]. OBSTETRICS AND GYNECOLOGY, 2008, 111 (02): : 526 - 528
  • [23] ADVANCED-CARCINOMA OF THE PROSTATE - TREATMENT WITH A GONADOTROPIN-RELEASING HORMONE AGONIST
    ALLEN, JM
    OSHEA, JP
    MASHITER, K
    WILLIAMS, G
    BLOOM, SR
    [J]. BMJ-BRITISH MEDICAL JOURNAL, 1983, 286 (6378): : 1607 - 1609
  • [24] Sertraline in the treatment of depression associated with gonadotropin-releasing hormone agonist therapy
    Warnock, JK
    Bundren, JC
    Morris, DW
    [J]. BIOLOGICAL PSYCHIATRY, 1998, 43 (06) : 464 - 465
  • [25] Sperm to zona pellucida binding depends on the use of a gonadotropin-releasing hormone agonist or a gonadotropin-releasing hormone antagonist
    Schröder, AK
    Schöpper, B
    Al-Hasani, S
    Löning, M
    Diedrich, K
    Ludwig, M
    [J]. FERTILITY AND STERILITY, 2003, 79 (03) : 648 - 650
  • [27] Effects of short-term treatment of a gonadotropin-releasing hormone agonist on the follicular development and gonadotropin secretion in the rat
    Krishna, A
    Srivastava, RK
    Sridaran, R
    [J]. ENDOCRINE RESEARCH, 1996, 22 (03) : 299 - 310
  • [28] Model of gonadotropin-releasing hormone and gonadotropin-releasing hormone complex
    Viroj Wiwanitkit
    [J]. Sexuality and Disability, 2006, 24 : 175 - 178
  • [29] Resolution of Uterine Arteriovenous Malformation and Successful Pregnancy After Treatment With a Gonadotropin-Releasing Hormone Agonist
    Nonaka, Taro
    Yahata, Tetsuro
    Kashima, Katsunori
    Tanaka, Kenichi
    [J]. OBSTETRICS AND GYNECOLOGY, 2011, 117 (02): : 452 - 455
  • [30] Review of Outcomes After Cessation of Gonadotropin-releasing Hormone Agonist Treatment of Girls with Precocious Puberty
    Thornton, Paul
    Silverman, Lawrence A.
    Geffner, Mitchell E.
    Neely, E. Kirk
    Gould, Errol
    Danoff, Theodore M.
    [J]. PEDIATRIC ENDOCRINOLOGY REVIEWS PER, 2014, 11 (03) : 306 - 317